会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PLANARIZATION FILMS FOR ADVANCED MICROELECTRONIC APPLICATIONS AND DEVICES AND METHODS OF PRODUCTION THEREOF
    • 用于高级微电子应用的平面薄膜及其制造方法
    • WO2005017617A1
    • 2005-02-24
    • PCT/US2003/034347
    • 2003-10-27
    • HONEYWELL INTERNATIONAL INCHUANG, WeiKENNEDY, JosephKATSANES, Ronald
    • HUANG, WeiKENNEDY, JosephKATSANES, Ronald
    • G03C1/00
    • H01L21/02118C04B26/12C04B2111/00482C08J7/02C08J2361/00C23F1/10C23F1/44C23F3/00C23F3/04H01L21/31051H01L21/312Y10T428/31942C04B2103/0093C04B2103/40
    • A planarization composition is disclosed herein that comprises: a) a structural constituent; and b) a solvent system, wherein the solvent system is compatible with the structural constituent and lowers the lowers at least one of the intermolecular forces or surface forces components of the planarization composition. A film that includes this planarization composition is also disclosed. In addition, another planarization composition is disclosed herein that comprises: a) a cresol-based polymer compound; and b) a solvent system comprising at least one alcohol and at least one ether acetate-based solvent. A film that includes this planarization composition is also disclosed. A layered component is also disclosed herein that comprises: a) a substrate having a surface topography; and b) a planarization composition or a film such as those described herein, wherein the composition is coupled to the substrate. Methods of forming a planarization compositions are also disclosed herein that comprise: a) providing a structural constituent; b) providing a solvent system, wherein the solvent system is compatible with the structural constituent and lowers at least one of the intermolecular forces or surface forces components of the planarization composition; and c) blending the structural constituent and the solvent system to form a planarization composition. Methods of forming a film are also disclosed that comprise: a) providing a planarization composition such as those disclosed herein; and b) evaporating at least part of the solvent system to form a film.
    • 本文公开了一种平面化组合物,其包括:a)结构成分; 和b)溶剂体系,其中所述溶剂体系与所述结构组分相容并降低所述平坦化组合物的至少一种分子间力或表面力组分。 还公开了包含该平坦化组合物的膜。 此外,本文公开了另外的平坦化组合物,其包括:a)甲酚基聚合物化合物; 和b)包含至少一种醇和至少一种乙酸乙烯酯类溶剂的溶剂体系。 还公开了包含该平坦化组合物的膜。 本文还公开了一种分层组件,其包括:a)具有表面形貌的衬底; 和b)平面化组合物或诸如本文所述的那些的膜,其中所述组合物与所述基材偶联。 本文还公开了形成平坦化组合物的方法,其包括:a)提供结构成分; b)提供溶剂体系,其中所述溶剂体系与所述结构组分相容并降低所述平坦化组合物的分子间力或表面力组分中的至少一种; 和c)将结构成分和溶剂体系混合以形成平坦化组合物。 还公开了形成膜的方法,其包括:a)提供诸如本文公开的那些的平坦化组合物; 和b)蒸发至少部分溶剂系统以形成膜。
    • 5. 发明申请
    • METHODS AND COMPOSITIONS FOR DETERMINING VIRUS SUSCEPTIBILITY TO INTEGRASE INHIBITORS
    • 用于确定集成抑制剂病毒易感性的方法和组合物
    • WO2012116371A1
    • 2012-08-30
    • PCT/US2012/026794
    • 2012-02-27
    • LABORATORY CORPORATION OF AMERICA HOLDINGSHUANG, WeiPETROPOULOS, Christos John
    • HUANG, WeiPETROPOULOS, Christos John
    • C12Q1/70
    • C12Q1/703C12Q2600/106C12Q2600/156
    • Methods and compositions for the efficient and accurate determination of HIV susceptibility to an integrase inhibitor and/or HIV replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an HIV integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the HIV has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference HIV. In certain embodiments, the HIV also contains one or more secondary mutations in integrase. Also provided are methods for determining the selective advantage of a mutation or mutation profile based on the difficulty to create the mutation, and its effect on susceptibility to an integrase inhibitor or replication capacity.
    • 提供了有效和准确地确定对整合酶抑制剂和/或HIV复制能力的HIV敏感性的方法和组合物。 在某些方面,所述方法包括在生物样品中检测编码HIV整合酶的核酸,所述核酸编码包含143位密码子的初级突变,其中143位密码子的突变不编码精氨酸(R)或半胱氨酸(C),其中 生物样品中整合酶编码核酸的存在表明HIV相对于参考HIV具有降低的对整合酶抑制剂的易感性或改变的复制能力。 在某些实施方案中,HIV还含有整合酶中的一个或多个次要突变。 还提供了基于产生突变的难度确定突变或突变特征的选择性优势的方法及其对整合酶抑制剂或复制能力的易感性的影响。